Manchester Capital Management LLC Buys 113 Shares of Danaher Co. (NYSE:DHR)

Manchester Capital Management LLC grew its holdings in shares of Danaher Co. (NYSE:DHR) by 2.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,515 shares of the conglomerate’s stock after buying an additional 113 shares during the quarter. Manchester Capital Management LLC’s holdings in Danaher were worth $1,037,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. FMR LLC grew its stake in Danaher by 15.8% in the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after acquiring an additional 3,217,631 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Danaher by 3.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock worth $1,417,342,000 after purchasing an additional 148,251 shares during the last quarter. Fisher Asset Management LLC grew its holdings in Danaher by 2.6% in the third quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock worth $1,265,725,000 after purchasing an additional 116,299 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Danaher by 17.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after purchasing an additional 535,254 shares during the last quarter. Finally, Montrusco Bolton Investments Inc. grew its holdings in Danaher by 0.6% in the fourth quarter. Montrusco Bolton Investments Inc. now owns 1,715,826 shares of the conglomerate’s stock worth $382,936,000 after purchasing an additional 9,942 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. This represents a 21.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 11.10% of the stock is currently owned by company insiders.

Danaher Price Performance

Shares of DHR stock opened at $206.66 on Friday. The firm’s 50-day moving average is $230.00 and its two-hundred day moving average is $249.96. The company has a market capitalization of $149.26 billion, a PE ratio of 39.14, a price-to-earnings-growth ratio of 2.68 and a beta of 0.83. Danaher Co. has a 12 month low of $196.80 and a 12 month high of $281.70. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05.

Danaher (NYSE:DHR) last announced its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the prior year, the company posted $2.09 EPS. Analysts predict that Danaher Co. will post 7.67 earnings per share for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.52%. The ex-dividend date of this dividend was Friday, December 27th. Danaher’s dividend payout ratio (DPR) is presently 20.45%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Stifel Nicolaus raised their price target on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a report on Wednesday, October 23rd. UBS Group decreased their price target on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Wells Fargo & Company reduced their target price on shares of Danaher from $280.00 to $240.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. Stephens reissued an “overweight” rating and set a $315.00 target price on shares of Danaher in a report on Wednesday, October 23rd. Finally, Citigroup cut their price objective on shares of Danaher from $285.00 to $265.00 and set a “buy” rating for the company in a report on Thursday, January 30th. Seven research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.